Bewersdorf, Jan Philipp http://orcid.org/0000-0003-3352-0902
Shallis, Rory M.
Sharon, Elad
Park, Silvia
Ramaswamy, Rahul
Roe, Caroline E.
Irish, Jonathan M.
Caldwell, Anne
Wei, Wei
Yacoub, Abdulraheem
Madanat, Yazan F.
Zeidner, Joshua F.
Altman, Jessica K.
Odenike, Olatoyosi
Yerrabothala, Swaroopa
Kovacsovics, Tibor
Podoltsev, Nikolai A.
Halene, Stephanie
Little, Richard F.
Piekarz, Richard
Gore, Steven D.
Kim, Tae Kon
Zeidan, Amer M.
Funding for this research was provided by:
National Cancer Institute
Article History
Received: 28 September 2023
Accepted: 13 November 2023
First Online: 1 December 2023
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committees at all participating sites.
: RMS received honoraria from BMS and Gilead. AY had an advisory role for Incyte, CTI Pharma, Pharmaessentia, Pfizer, Novartis, ACCELERON PHARMA, Servier, AbbVie, Apellis, Gilead, Notable Labs, and Celgene. JFZ received research funding from AbbVie, Gilead, Arog, Astex, Jazz, Merck, Stemline, Sumitomo Dainippon Pharma, Syndax, and Takeda and had a consultancy/received honoraria from AbbVie, BMS, Genentech, Gilead, Immunogen, Servier, and Shattuck Labs. JKA was a member of Data Monitoring Committee for GlycoMimetics and a had consulting or Advisory Role for AbbVie, Astellas Pharma, BioSight, Bluebird Bio, Curio, Daiichi Sankyo, Gilead, Kura Oncology, Kymera, MDEducation, Rigel, Stemline Therapeutics, and Syros. JKA received research funding (all to institution) from AbbVie, Agios, ALX Oncology, Amgen, Amphivena, Aprea AB, Aptose Biosciences, Astellas, Pharma, BioSight, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cyclacel, Fujifilm, Immunogen, Kartos Therapeutics, Kura Oncology, Loxo, and Pfizer. YFM has received honoraria/consulting fees from Kura Oncology, BluePrint Medicines, GERON, OncLive, and MD Education. YFM participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphosys, Taiho Oncology, Rigel Pharmaceuticals, and Novartis. YFM received travel reimbursement from Blueprint Medicines, MD Education, and Morphosys. NAP received consulting fees from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene/Bristol-Myers Squibb, CTI BioPharma, PharmaEssentia, Constellation Pharmaceuticals, and AbbVie; other financial support for serving on an Independent Data Review Committee for Cogent Biosciences. OO had a consultancy with Abbvie; Impact Biomedicines; Celgene; Novartis; BMS; Taiho Pharmaceutical; CTI; Threadwell therapeutics; and Bristol-Myers Squibb/Celgene and received research funding (all to the institution) from Celgene, Incyte, Astex Pharmaceuticals, NS Pharma, Abbvie, Janssen Oncology, OncoTherapy Science, Agios, AstraZeneca, CTI BioPharma Corp, Kartos Therapeutics, Aprea AB. SH had a consultancy with Forma Therapeutics. TKK received research funding from Nextcure and had a consultancy with Agenus. AMZ participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Servier, Boehringer-Ingelheim, Novartis, Astellas, Daiichi Sankyo, Geron, Taiho, Seattle Genetics, Otsuka, BeyondSpring, Takeda, Ionis, Amgen, Janssen, Genentech, Epizyme, Syndax, Gilead, Kura, Chiesi, ALX Oncology, BioCryst, Notable, Orum, Mendus, Zentalis, Schrodinger, Regeneron, Syros, and Tyme. None of these relationships was related to the content of this manuscript. All other authors report no relevant conflicts of interest.
: Informed consent was obtained from all individual participants included in the study.